Wasano Koichiro, Sakurai Kouhei, Kawasaki Taiji, Kusafuka Kimihide, Kasahara Masao, Kondo Naoki, Inada Ken-Ichi, Ogawa Kaoru
Department of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Department of Otolaryngology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Rare Tumors. 2018 Sep 19;10:2036361318798867. doi: 10.1177/2036361318798867. eCollection 2018.
Salivary duct carcinoma is a relatively rare salivary cancer, and most cases are androgen receptor -positive. Salivary duct carcinoma growth is suggested to be androgen dependent, which can reportedly be controlled by androgen deprivation therapy. However, the effectiveness and underlying molecular mechanisms of androgen deprivation therapy for salivary duct carcinoma remain unknown. We report a salivary duct carcinoma case (65-year-old man) arising from the parotid gland with metastasis to the neck lymph nodes and lungs. Androgen deprivation therapy was performed according to the same protocol for prostate cancer treatment. Expression levels of androgen receptor and FOXA1 (forkhead box A1) were immunohistochemically analyzed before and after androgen deprivation therapy. Although the tumor volume was partially diminished during the first 3 months, acquired resistance to androgen deprivation therapy occurred. FOXA1 was not detected in parotid gland after androgen deprivation therapy, whereas androgen receptor expression was positive. FOXA1 expression might be related to acquired androgen deprivation therapy resistance in salivary duct carcinoma.
涎腺导管癌是一种相对罕见的涎腺癌，大多数病例为雄激素受体阳性。涎腺导管癌的生长被认为依赖雄激素，据报道雄激素剥夺疗法可以控制其生长。然而，雄激素剥夺疗法对涎腺导管癌的有效性及潜在分子机制仍不清楚。我们报告了一例来自腮腺的涎腺导管癌病例（65岁男性），该病例已转移至颈部淋巴结和肺部。按照前列腺癌治疗的相同方案进行了雄激素剥夺治疗。在雄激素剥夺治疗前后，通过免疫组织化学分析了雄激素受体和FOXA1（叉头框A1）的表达水平。尽管在最初3个月肿瘤体积部分缩小，但出现了对雄激素剥夺治疗的获得性耐药。雄激素剥夺治疗后在腮腺中未检测到FOXA1，而雄激素受体表达为阳性。FOXA1表达可能与涎腺导管癌对雄激素剥夺治疗的获得性耐药有关。
